首页> 外文会议>Polymer reaction engineering X >POLY(HPMA)-BASED COPOLYMERS WITH BIODEGRADABLE SIDE CHAINS ABLE TO SELF ASSEMBLE INTO NANOPARTICLES
【24h】

POLY(HPMA)-BASED COPOLYMERS WITH BIODEGRADABLE SIDE CHAINS ABLE TO SELF ASSEMBLE INTO NANOPARTICLES

机译:具有可生物降解侧链的聚(HPMA)基共聚物,可自组装成纳米颗粒

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Poly(N-(2-Hydroxypropyl) methacrylamide) (poly(HPMA)) is gaining pharmaceutical attention in replacement to PEG as a hydrophilic stabilizer for polymer nanoparticles (NPs) devoted to systemic administration.This is due to its biocompatibility, prolonged circulation time and, compared to PEG, to the avoidance of allergic reactions and of the accelerated blood clearance effect.In this work, a lipophilic HPMA-based macromonomer with a predetermined and controllable structure is synthesized for the first time attaching a short oligo(caprolactone) chain obtained via Ring Opening Polymerization (ROP) to the HPMA using a succinic acid unit as a spacer. This biodegradable monomer (hereinafter HPMA-CL) was then used to synthesize well-defined amphiphilic block copolymers comprising a hydrophilic poly(HPMA) block and a hydrophobic poly(HPMA-CL) segment via Reversible Addition-Fragmentation Transfer (RAFT) polymerization. The combination of ROP and RAFT allows the production of a library of polymers with a predetermined and controlled structure that are able to self-assemble in water into biodegradable NPs with different size. In particular, such NPs are designed to degrade in aqueous environment into completely water soluble poly(HPMA), with a molecular weight that is below the critical threshold for the renal excretion. This is a very important feature since it allows to avoid polymer accumulation into the body once the NPs are injected.The degradation time is a function of the number of caprolactone units in the HPMA-CL macromonomer and of its degree of polymerization in the NP forming copolymer. Then, the polymer structure can be adjusted to obtain the desired degradation time. Finally, the possibility for such nanoparticles to physically incorporate and mediate the release of a lipophilic antineoplastic drug was evaluated in the case of Trabectedin. The formulation proved to be biocompatible and to sustainedly release the drug for up to 24 hours.
机译:聚(N-(2-羟丙基)甲基丙烯酰胺)(聚(HPMA))在取代PEG用作全身性给药的聚合物纳米颗粒(NP)的亲水稳定剂方面正受到制药界的关注,这是由于其生物相容性,延长的循环时间在这项工作中,首次合成了具有预定可控结构的基于亲脂性HPMA的大分子单体,它首次连接了一条短寡聚(己内酯)链通过使用琥珀酸单元作为间隔基的开环聚合(ROP)到HPMA的方法获得。然后,通过可逆加成-断裂转移(RAFT)聚合反应,将该可生物降解的单体(下文称为HPMA-CL)用于合成定义明确的两亲嵌段共聚物,其包含亲水性聚(HPMA)嵌段和疏水性聚(HPMA-CL)链段。 ROP和RAFT的组合允许生产具有预定和受控结构的聚合物库,该结构能够在水中自组装为具有不同大小的可生物降解的NP。特别地,此类NP被设计成在水性环境中降解为分子量低于肾排泄临界阈值的完全水溶性的聚(HPMA)。这是非常重要的功能,因为一旦注射NP即可避免聚合物积累到体内。降解时间是HPMA-CL大分子单体中己内酯单元数量及其在NP形成过程中聚合度的函数共聚物。然后,可以调节聚合物结构以获得所需的降解时间。最后,在特拉贝丁丁的情况下,评估了这种纳米颗粒物理掺入和介导亲脂性抗肿瘤药释放的可能性。该制剂被证明具有生物相容性,可以持续释放药物长达24小时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号